| Name | 2',5'-Dideoxyadenosine |
| Description | 2',5'-Dideoxyadenosine is a potent and non-competitive adenylyl cyclase inhibitor, binding to the P-site with an IC50 of 3 μM. |
| Cell Research | Primary hippocampal neurons. Concentration: 10 μM. Incubation Time: 30 min [3] |
| Animal Research | Male Wistar rats (3-4 months old).Dosage: 0.1 mg/kg.Administration: i.p.; 15 min pre-treated [3] |
| In vitro | 2',5'-Dideoxyadenosine (20-150 mM), like adenosine, dependently and reversibly inhibits the positive inotropic and chronotropic effect of beta-adrenergic stimulation with isoproterenol (8-54 pmol) up to 70% and 50%, respectively [2]. 2',5'-Dideoxyadenosine (10 μM, 30 min) reduces cAMP production and blocks the phosphorylation of GluA1 at Ser845 induced by carbachol (CCh). 2',5'-Dideoxyadenosine (10 μM, 30 min) blocks CCh-induced increase of phosphorylation of Akt and attenuates CCh-induced phosphorylation of Ser2448 [3]. |
| In vivo | 2',5'-Dideoxyadenosine (0.1 mg/kg; i.p.; 15 min pre-treated) completely inhibits the natriuretic, diuretic, and K+ and Cl- sparing effects of Fr-EtOAc in rats [4]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 2.35 mg/mL (9.99 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (4.25 mM), Sonication is recommended.
|
| Keywords | P-site | nucleoside | Inhibitor | inhibit | heart | cyclase | Beta Receptor | antiadrenergic | analog | AdrenergicReceptor | Adrenergic Receptor | Adenylylcyclase | Adenylyl cyclase (AC) | Adenylyl cyclase | adenylyl | Adenylate Cyclase | 2',5'-Dideoxyadenosine | 2',5'Dideoxyadenosine | 2',5' Dideoxyadenosine |
| Inhibitors Related | Adiphenine hydrochloride | Pilocarpine nitrate | Clozapine N-Oxide | Urethane | Ribavirin | Octopamine hydrochloride | Dexmedetomidine hydrochloride | D-Menthol | Choline chloride | Propoxur | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Compound Library | Human Metabolite Library | Nucleotide Compound Library |
United States
